Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to improve cancer care. The company's lead product is NERLYNX an oral formulation of neratinib approved for the treatment of certain HER2 positive breast cancers. NERLYNX has received approval in the United States for the extended adjuvant treatment of early stage HER2 overexpressed breast cancer following adjuvant trastuzumab based therapy and for use in combination with capecitabine for the treatment of advanced or metastatic HER2 positive breast cancer after two or more prior anti HER2 based regimens. In addition, Puma Biotechnology has in licensed alisertib from Takeda and is advancing its development for hormone receptor positive breast cancer and small cell lung cancer. Alisertib is an investigational small molecule inhibitor of Aurora Kinase A that disrupts mitosis leading to tumor cell death. Prior to licensing, alisertib was tested in over 1,300 patients across 22 company sponsored trials providing a substantial safety database.

The company generates revenue primarily from sales of NERLYNX in the United States through a dedicated specialty sales force of approximately 35 representatives as of the end of 2025. Outside the United States, Puma Biotechnology earns royalties and milestone payments from sublicense agreements that permit third parties to commercialize NERLYNX in regions including Europe, Canada, Latin America, Asia and the Middle East. Under its license agreements, the company pays royalties in the range of 10% to 15% of net sales and may receive milestone payments upon achieving regulatory and commercial goals. Puma Biotechnology received an upfront license fee of $7 million from Takeda for alisertib and may be eligible for additional milestone payments of up to $287 million if development and sales targets are met. Future revenue may arise from the commercialization of alisertib if it receives regulatory approval for the indications being studied.

Puma Biotechnology operates in a highly competitive oncology market where it faces large pharmaceutical and biotechnology companies such as Genentech, Roche, Novartis, Lilly, Merck, Pfizer and AbbVie. For its HER2 positive breast cancer franchise, competitors include trastuzumab, pertuzumab, lapatinib, antibody drug conjugates and tyrosine kinase inhibitors. For alisertib in small cell lung cancer and hormone receptor positive breast cancer, competitors include emerging Aurora Kinase A inhibitors and established chemotherapies. The company's competitive advantages stem from a proprietary nerve targeted therapy in neratinib, an exclusive global license to alisertib, a direct sales team in the United States, and a network of international sublicense partners that broaden geographic reach without the need for extensive internal infrastructure. Additionally, Puma Biotechnology benefits from a strong intellectual property portfolio that includes numerous patents covering neratinib composition formulations and uses, which may provide market exclusivity until at least 2030 in the United States.

The company serves patients with HER2 positive breast cancer hormone receptor positive breast cancer and small cell lung cancer as well as the health care providers who treat them including oncologists hospitals and clinics. In the United States, Puma Biotechnology distributes NERLYNX through specialty pharmacy partners such as Accredo, CVS, ONCO 360, Optum and Biologics and through specialty distributor partners such as McKesson, ASD/Oncology Supply, Cardinal Health, DMS Pharmaceutical Group and Bio Care. Outside the United States, the company relies on sublicense partners to deliver its therapies to local health care systems and patients.